Trump's 100% tariff on patented drugs has limited impact on Indian pharma, rising protectionism a concern:

The recent decision by US President Donald Trump to impose a 100 per cent tariff on patented pharmaceutical imports to US is unlikely to cause immediate disruption to Indian drugmakers, as the move largely targets branded medicines while exempting generics and biosimilars, said Siddharth Mittal, CEO and Managing Director of Biocon Limited.